Related Experiment Video
Updated: Aug 8, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
[Influenza vaccination in the elderly population in Mexico: economic considerations]
Juan Pablo Gutiérrez1, Stefano M Bertozzi
1División de Economía y Políticas de la Salud, Centro de Investigación en Sistemas de Salud, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México. jpgutier@insp.mx
Objective:
To estimate costs and health outcomes that could be attained by an influenza vaccination program in adults 65 years of age and older in Mexico.
Material And Methods:
Between June and October 2004, a model was constructed to estimate the number of life years lost due to influenza and the fraction that could be prevented by vaccination among adults 65 years of age and older. The model also allowed the estimation of the net cost of a vaccination program, including both the cost of delivering the vaccine and savings from prevented infections and their treatment costs.
Results:
Using two scenarios of vaccine effectiveness, between 7 454 and 11 169 life years could saved by the vaccine if given to all adults 65 years and older in Mexico, with a net cost per life year saved between 13 301 and 21 037 Mexican pesos (about dollar 1 210 and dollar 1 910 US dollars).
Discussion:
Influenza vaccination among the elderly in Mexico would result in savings per life year saved well below the Mexican gross domestic product (GDP) per capita, suggesting, even without examining alternative uses for these resources, that this is a cost effective intervention in Mexico and probably also in other middle-income developing countries.
Related Concept Videos
Vaccinations
Drug Dosing: Geriatric Patients
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Pharmacodynamics in Geriatric Patients: Effects of Age
Influenza

